Evidence map›Paper›PMID 32380961›Full record

Observational studyBMC nephrology2020

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.

Gregory A Nichols, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Teresa M Kimes, A Gabriela Rosales, Sibylle J Hauske

Erratum issuedAbstract readComparative StudyObservational Study
In one paragraph

Observational study in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Preventable Hospitalizations and Kidney Care.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Diabetes: A Subspecialty of Medicine and a Matter of Public Health.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Gregory A NicholsKaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, Oregon, USA. greg.nichols@kpchr.org.
Anouk Déruaz-LuyetBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Kimberly G BrodoviczBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Teresa M KimesKaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, Oregon, USA.
A Gabriela RosalesKaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, Oregon, USA.
Sibylle J HauskeBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies of progression of kidney dysfunction typically focus on renal replacement therapy or percentage decline in estimated glomerular filtration rate (eGFR) as outcomes. Our aim was to compare real-world patients with and without T2D to estimate progression from and to clinically defined categories of kidney disease and all-cause mortality.

methodsThis was an observational cohort study of 31,931 patients with and 33,201 age/sex matched patients without type 2 diabetes (T2D) who had a serum creatinine and urine albumin-to-creatinine ratio (UACR) or dipstick proteinuria (DP) values. We used the first available serum creatinine value between 2006 and 2012 to calculate baseline eGFR and categorized them and the corresponding UACR/DP values using the Kidney Disease Improving Global Outcomes (KDIGO) categories. To assess our primary outcomes, we extracted probabilities of eGFR progression or mortality from life-table analyses and conducted multivariable Cox regression analyses of relative risk adjusted for age, sex, race/ethnicity, smoking, ischemic heart disease, heart failure, and use of renal-angiotensin-aldosterone system inhibitors.

resultsPatterns of eGFR decline were comparable among patients with vs. without T2D with larger percentage declines at higher albuminuria levels across all eGFR categories. eGFR decline was generally larger among T2D patients, particularly in those with severely increased albuminuria. Across all CKD categories, risk of progression to the next higher category of eGFR was substantially increased with increasing albuminuria. For example, the risk was 23.5, 36.2, and 65.1% among T2D patients with eGFR 30-59 ml/min/1.73m

conclusionsPresence of albuminuria was associated with accelerated eGFR decline independent of T2D. Risk for adverse outcomes was remarkably high among patients with CKD and normal to mildly increased albuminuria levels. Independent of T2D or albuminuria, a substantial risk for adverse outcomes exists for CKD patients in a routine care setting.

Indexed as

Disease ProgressionMortalityAgedAlbuminuriaCohort StudiesComorbidityCreatinineDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateHumansLife TablesLongitudinal StudiesMaleMiddle AgedOregonCreatinineDiabetesElectronic health recordsEpidemiologyRenal disease

Identifiers

PMID32380961
PMCPMC7203828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.